17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells
- 1 September 2015
- journal article
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 47 (5) , 373-381
Abstract
Heat shock protein 90 (Hsp90) is an attractive therapeutic target. Geldanamycin (GA), the first identified Hsp90 inhibitor, exhibited potent antitumor activity, but possessed significant hepatotoxicity. To overcome the hepatotoxicity derived from the quinone structure of GA, a non-quinone GA derivative 17-demethoxy-reblastatin (17-DR) was obtained from a genetically modified strain of Streptomyces hygroscopicus. In the present study, we examined the anticancer effects of 17-DR on human hepatocellular carcinoma (HCC) cell lines HepG2 and SMMC7721, and its underlying mechanisms. The results indicated that 17-DR could concentration-dependently inhibit the proliferation, and decrease the colony formation in HCC cells. It also induced significant apoptosis in HCC cells, which was mediated by mitochondria via a caspase-dependent pathway. The mechanisms involved in 17-DR-induced apoptosis included the downregulation of myeloid cell leukemia-1 (Mcl-1), and upregulation of Bcl-2 antagonist killer 1 (Bak). And the upregulated Bak expression resulted from downregulation of Mcl-1 played an essential role in this process. Taken together, these results indicated that 17-DR possessed potent anticancer effects on HCC cells by inhibiting cell proliferation and inducing apoptosis.Keywords
This publication has 30 references indexed in Scilit:
- Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitorsEuropean Journal of Medicinal Chemistry, 2014
- Emerging Trends in Hepatocellular Carcinoma: Focus on Diagnosis and TherapeuticsClinical Medicine Insights: Oncology, 2014
- Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivativesExpert Opinion on Therapeutic Patents, 2013
- Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublinesOncology Reports, 2012
- Anti-cancer drug discovery and developmentCommunicative & Integrative Biology, 2012
- Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak‐independent death of cancer cellsEMBO Molecular Medicine, 2012
- NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibitionGenes & Development, 2007
- Breaking the mitochondrial barrierNature Reviews Molecular Cell Biology, 2001
- The Hallmarks of CancerCell, 2000
- Hsp90 as an anti-cancer targetDrug Resistance Updates, 1999